Dynavax Technologies (NASDAQ:DVAX – Get Free Report) and Janux Therapeutics (NASDAQ:JANX – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.
Analyst Recommendations
This is a summary of recent ratings and price targets for Dynavax Technologies and Janux Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dynavax Technologies | 0 | 1 | 3 | 0 | 2.75 |
| Janux Therapeutics | 0 | 0 | 7 | 0 | 3.00 |
Dynavax Technologies presently has a consensus price target of $25.00, indicating a potential upside of 122.02%. Janux Therapeutics has a consensus price target of $61.33, indicating a potential upside of 29.78%. Given Dynavax Technologies’ higher possible upside, analysts plainly believe Dynavax Technologies is more favorable than Janux Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Dynavax Technologies | -2.75% | -1.08% | -0.66% |
| Janux Therapeutics | -721.18% | -17.88% | -15.95% |
Volatility and Risk
Dynavax Technologies has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 4.18, suggesting that its stock price is 318% more volatile than the S&P 500.
Earnings and Valuation
This table compares Dynavax Technologies and Janux Therapeutics’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dynavax Technologies | $232.28 million | 6.32 | -$6.39 million | ($0.06) | -186.80 |
| Janux Therapeutics | $8.08 million | 302.99 | -$58.29 million | ($1.34) | -35.37 |
Dynavax Technologies has higher revenue and earnings than Janux Therapeutics. Dynavax Technologies is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
97.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 3.0% of Dynavax Technologies shares are held by insiders. Comparatively, 35.4% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Dynavax Technologies beats Janux Therapeutics on 8 of the 13 factors compared between the two stocks.
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
About Janux Therapeutics
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
